AEterna Zentaris Completes Enrollment in Perifosine Trial

November 14, 2007

Canadian drugmaker AEterna Zentaris has completed patient recruitment for the company’s Phase II trial of perifosine in nonsmall cell lung cancer (NSCLC).

The European, multicenter, randomized, double-blind, placebo-controlled trial will assess the efficacy and safety of a 150-mg daily dose of perifosine combined with radiotherapy in 160 patients with inoperable Stage III NSCLC.

David Mazzo, AEterna Zentaris’ president and CEO, said patients will be followed for one year following treatment, and the company expects to announce top-line results at the end of 2008.